The company already has more than 20 subsidiaries developing treatments for monogenic diseases and genetically defined cancers, but its deal-making pace has not slowed.

Scrip talked to Leo Pharma's new CEO Catherine Mazzacco about going up against big biopharma players in dermatology and plans to file tralokinumab in 2020.

A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.

The company emerged in 2017 with $135m to spin out rare genetic disease-focused subsidiaries. Now with 18 start-ups and two near-term filings for drug approvals, BridgeBio will fund existing programs as they progress and continue to buy new assets.